These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 35202996)

  • 1. An optimal extended-infusion dosing of cefepime and ceftazidime in critically ill patients with continuous renal replacement therapy.
    Sember AM; LoFaso ME; Lewis SJ
    J Crit Care; 2022 Jun; 69():154011. PubMed ID: 35202996
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Optimal antipseudomonal ꞵ-lactam drug dosing recommendations in critically-ill Asian patients receiving CRRT.
    Jang SM; Lewis SJ; Rhie SJ
    J Crit Care; 2022 Dec; 72():154172. PubMed ID: 36270240
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacokinetics and Pharmacodynamics of Extended-Infusion Cefepime in Critically Ill Patients Receiving Continuous Renal Replacement Therapy: A Prospective, Open-Label Study.
    Philpott CD; Droege CA; Droege ME; Healy DP; Courter JD; Ernst NE; Harger NJ; Foertsch MJ; Winter JB; Carter KE; Van Fleet SL; Athota K; Mueller EW
    Pharmacotherapy; 2019 Nov; 39(11):1066-1076. PubMed ID: 31549737
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A Monte Carlo Simulation Approach for Beta-Lactam Dosing in Critically Ill Patients Receiving Prolonged Intermittent Renal Replacement Therapy.
    Jang SM; Gharibian KN; Lewis SJ; Fissell WH; Tolwani AJ; Mueller BA
    J Clin Pharmacol; 2018 Oct; 58(10):1254-1265. PubMed ID: 29746711
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cefepime dosing regimens in critically ill patients receiving continuous renal replacement therapy: a Monte Carlo simulation study.
    Chaijamorn W; Charoensareerat T; Srisawat N; Pattharachayakul S; Boonpeng A
    J Intensive Care; 2018; 6():61. PubMed ID: 30221005
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antibiotic dosing recommendations in critically ill patients receiving new innovative kidney replacement therapy.
    Lewis SJ; Mueller BA
    BMC Nephrol; 2024 Feb; 25(1):73. PubMed ID: 38413858
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cefepime Population Pharmacokinetics and Target Attainment in Critically Ill Patients on Continuous Renal Replacement Therapy.
    Al-Shaer MH; Philpott CD; Droege CA; Courter JD; Healy DP; Droege ME; Ernst NE; Mueller EW; Peloquin CA
    Antimicrob Agents Chemother; 2021 May; 65(6):. PubMed ID: 33722885
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Letter to the Editor : "An optimal extended-infusion dosing of cefepime and ceftazidime in critically ill patients with continuous renal replacement therapy".
    Honore PM; Redant S; Djimafo P; Preseau T; Cismas BV; Kaefer K; Barreto Gutierrez L; Anane S; Gallerani A; Attou R
    J Crit Care; 2022 Aug; 70():154058. PubMed ID: 35561558
    [No Abstract]   [Full Text] [Related]  

  • 9. Optimal Meropenem Dosing Regimens in Patients Undergoing Continuous Renal Replacement Therapy: Systematic Review and Monte Carlo Simulations.
    Charoensareerat T; Chaijamorn W; Kerdnimith P; Kosumwisaisakul N; Teeranaew P; Rungkitwattanakul D; Boonpeng A; Srisawat N; Pattharachayakul S
    Blood Purif; 2023; 52(6):503-515. PubMed ID: 37231811
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cefepime Population Pharmacokinetics, Antibacterial Target Attainment, and Estimated Probability of Neurotoxicity in Critically Ill Patients.
    Bilal M; Zoller M; Fuhr U; Jaehde U; Ullah S; Liebchen U; Büsker S; Zander J; Babouee Flury B; Taubert M
    Antimicrob Agents Chemother; 2023 Jul; 67(7):e0030923. PubMed ID: 37366614
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antibiotic Dosing in Continuous Renal Replacement Therapy.
    Shaw AR; Mueller BA
    Adv Chronic Kidney Dis; 2017 Jul; 24(4):219-227. PubMed ID: 28778361
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Author response: "An optimal extended-infusion dosing of cefepime and ceftazidime in critically ill patients with continuous renal replacement therapy".
    Sember AM; LoFaso ME; Lewis SJ
    J Crit Care; 2022 Aug; 70():154059. PubMed ID: 35568021
    [No Abstract]   [Full Text] [Related]  

  • 13. Use of Monte Carlo Simulations to Determine Optimal Carbapenem Dosing in Critically Ill Patients Receiving Prolonged Intermittent Renal Replacement Therapy.
    Lewis SJ; Kays MB; Mueller BA
    J Clin Pharmacol; 2016 Oct; 56(10):1277-87. PubMed ID: 26919659
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Population pharmacokinetics and target attainment analyses to identify a rational empirical dosing strategy for cefepime in critically ill patients.
    An G; Creech CB; Wu N; Nation RL; Gu K; Nalbant D; Jimenez-Truque N; Fissell W; Patel PC; Fishbane N; Watanabe A; Rolsma S; Kirkpatrick CMJ; Landersdorfer CB; Winokur P
    J Antimicrob Chemother; 2023 Jun; 78(6):1460-1470. PubMed ID: 37071586
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antibiotic Exposure Profiles in Trials Comparing Intensity of Continuous Renal Replacement Therapy.
    Jang SM; Pai MP; Shaw AR; Mueller BA
    Crit Care Med; 2019 Nov; 47(11):e863-e871. PubMed ID: 31397714
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Population Pharmacokinetics and Dosing Optimization of Piperacillin-Tazobactam in Critically Ill Patients on Extracorporeal Membrane Oxygenation and the Influence of Concomitant Renal Replacement Therapy.
    Hahn J; Min KL; Kang S; Yang S; Park MS; Wi J; Chang MJ
    Microbiol Spectr; 2021 Dec; 9(3):e0063321. PubMed ID: 34937189
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Levetiracetam dosing in patients receiving continuous renal replacement therapy.
    Chaijamorn W; Charoensareerat T; Rungkitwattanakul D; Phunpon S; Sathienluckana T; Srisawat N; Pattharachayakul S
    Epilepsia; 2021 Sep; 62(9):2151-2158. PubMed ID: 34247386
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Population pharmacokinetics of polymyxin B in critically ill patients receiving continuous venovenous haemofiltration.
    Wang P; Xing H; Zhang F; Liu S; Lu Y; Zhang X; Yang J; Sun T
    Int J Antimicrob Agents; 2022 Jul; 60(1):106599. PubMed ID: 35526750
    [TBL] [Abstract][Full Text] [Related]  

  • 19. What is the optimal loading dose of broad-spectrum β-lactam antibiotics in septic patients? Results from pharmacokinetic simulation modelling.
    Delattre IK; Hites M; Laterre PF; Dugernier T; Spapen H; Wallemacq PE; Jacobs F; Taccone FS
    Int J Antimicrob Agents; 2020 Oct; 56(4):106113. PubMed ID: 32721604
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A Loading Micafungin Dose in Critically Ill Patients Undergoing Continuous Venovenous Hemofiltration or Continuous Venovenous Hemodiafiltration: A Population Pharmacokinetic Analysis.
    Garbez N; Mbatchi LC; Maseda E; Luque S; Grau S; Wallis SC; Muller L; Lipman J; Roberts JA; Lefrant JY; Roger C
    Ther Drug Monit; 2021 Dec; 43(6):747-755. PubMed ID: 33560097
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.